Skip to main content
    K

    Kezar Life Sciences Inc (KZR)

    Official site

    BIOTECHNOLOGY

    $7.29
    +0.00 (+0.00%)

    Last updated: May 11, 2026 at 5:00 PM ET

    Kezar Life Sciences Inc (KZR) Financials: Revenue, Profit and Cash Flow

    Updated May 11, 2026. Financial statements from company filings, amounts in US dollars.

    Kezar Life Sciences reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$56.03M, operating cash flow was -$51.78M and free cash flow was -$51.78M. The quarter ended Mar 31, 2026 had revenue of $0 and net income of -$5.76M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $59.11M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$7.00MN/A100.0%-1591.8%-1455.3%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Mar 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$7.00M$0$0$0$0$0$0$0
    Gross profit$0$0$7.00M$0$0$0$0$0$0$0
    Research and development$33.76M$65.74M$85.70M$51.01M$38.94M$30.98M$27.36M$18.14M$6.47M$7.37M
    Operating income-$59.11M-$90.61M-$111.42M-$71.16M-$54.66M-$42.95M-$37.34M-$24.73M-$8.75M-$8.99M
    Net income-$56.03M-$83.74M-$101.87M-$68.24M-$54.63M-$41.74M-$35.09M-$23.17M-$8.52M-$8.99M
    EBITDAN/AN/AN/AN/A-$51.29M-$41.09M-$37.02M-$24.51M-$8.57M-$8.84M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue$0$0$0$0$0$1.04M$0$0$0-$5.43M$7.00M$0
    Gross profit$0-$176.00K$0$0$0$521.00K$0$0$0-$280.00K$7.00M$0
    Operating income-$7.37M-$15.16M-$11.71M-$14.60M-$17.63M-$21.56M-$21.95M-$23.38M-$23.71M-$34.59M-$25.53M-$26.78M
    Net income-$5.76M-$14.55M-$11.23M-$13.70M-$16.56M-$20.22M-$20.31M-$21.55M-$21.66M-$32.26M-$23.10M-$24.31M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.33M by $69.55M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$76.65M$144.68M$221.24M$299.57M$217.93M$151.84M$89.51M$114.68M$54.22M$11.42M
    Current assets$75.73M$137.49M$206.95M$285.72M$211.65M$144.81M$81.13M$109.81M$52.33M$10.49M
    Cash and equivalents$71.88M$41.75M$35.49M$40.46M$62.88M$21.23M$14.95M$24.18M$51.03M$9.75M
    Total liabilities$6.57M$27.77M$33.66M$29.70M$21.06M$10.86M$11.47M$5.88M$1.98M$28.85M
    Short-term debt$2.33M$5.22M$0$2.56M$1.20M$1.04M$900.00KN/AN/AN/A
    Long-term debtN/A$5.11M$10.07M$9.83M$9.62MN/AN/AN/AN/AN/A
    Shareholder equity$70.07M$116.92M$187.57M$269.87M$196.88M$140.98M$78.05M$108.80M-$25.69M-$17.43M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$68.00M$76.65M$97.73M$109.12M$125.26M$144.68M$164.09M$179.92M$199.13M$221.24M$249.33M$263.38M
    Total liabilities$2.76M$6.57M$14.75M$17.34M$22.19M$27.77M$30.04M$29.24M$30.01M$33.66M$33.33M$31.10M
    Cash and equivalents$66.23M$71.88M$38.94M$34.37M$37.00M$41.75M$34.86M$28.28M$33.03M$35.49M$26.50M$28.11M
    Shareholder equity$65.24M$70.07M$82.98M$91.79M$103.07M$116.92M$134.05M$150.69M$169.12M$187.57M$215.99M$232.28M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$51.78M-$74.21M-$81.64M-$58.85M-$42.44M-$36.95M-$29.88M-$20.79M-$8.11M-$9.76M
    Capital expenditures$8.00K$29.00K$1.81M$1.58M$316.00K$194.00K$607.00K$1.12M$389.00K$132.00K
    Free cash flow-$51.78M-$74.24M-$83.45M-$60.42M-$42.75M-$37.14M-$30.48M-$21.91M-$8.50M-$9.89M
    Investing cash flow$92.46M$80.43M$76.05M-$91.39M-$28.44M-$56.50M$20.42M-$83.90M-$389.00K-$132.00K
    Financing cash flow-$10.59M$103.00K$638.00K$127.86M$112.58M$99.64M$272.00K$77.91M$49.76M$36.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-$7.45M-$11.96M-$9.83M-$12.79M-$17.19M-$16.82M-$17.49M-$17.03M-$22.86M-$18.98M-$20.20M-$21.60M
    Capital expenditures$0$0$0$0$8.00K$11.00K$18.00K$0$0$1.00K$136.00K$1.38M
    Free cash flow-$7.45M-$11.96M-$9.83M-$12.79M-$17.20M-$16.84M-$17.51M-$17.03M-$22.86M-$18.98M-$20.34M-$22.98M
    Last 12 quarters

    Frequently Asked Questions About KZR

    What is Kezar Life Sciences' annual revenue?

    Kezar Life Sciences reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Kezar Life Sciences profitable?

    No. Kezar Life Sciences reported net income of -$56.03M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does KZR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$51.78M minus capital expenditures of $8.00K produced free cash flow of -$51.78M.

    How much debt does Kezar Life Sciences have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.33M and cash and equivalents of $71.88M.